OTCMKTS:CVSI CV Sciences (CVSI) Stock Price, News & Analysis $0.03 0.00 (-6.89%) As of 02/27/2025 03:51 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest About CV Sciences Stock (OTCMKTS:CVSI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CV Sciences alerts:Sign Up Key Stats Today's Range$0.03▼$0.0350-Day Range$0.03▼$0.0552-Week Range$0.03▼$0.10Volume363,830 shsAverage Volume213,869 shsMarket Capitalization$5.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.Read More… Receive CVSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CV Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CVSI Stock News HeadlinesCV Sciences Disputes Stock Purchase Agreement TerminationFebruary 11, 2025 | tipranks.comCV Sciences unveils Aura Collection’s THC Fizz TabletsFebruary 6, 2025 | markets.businessinsider.comMost traders refer to weekends as dead days…Since the pandemic, the average mortgage payment has jumped from $1,427 to $2,047. That's an extra $600 every single month just vanishing from people's pockets. Meanwhile, credit card debt is hitting record highs, and savings accounts are at their lowest since 2008. Most folks are left with two options… Get a second job... or work overtime on weekends. But what if there was a third option? I just uncovered a shocking anomaly in the options market that could change everything... One that lets you target extra cash on days when most people make nothing - weekends. Think what that could mean for your monthly budget...February 28, 2025 | WealthPress (Ad)Hemp-Focused CV Sciences Expands Via New Cannabis Acquisition, Here's What Investors Need To KnowNovember 22, 2024 | benzinga.comCV Sciences to Acquire Extract Labs in $1.4M DealNovember 21, 2024 | marketwatch.comCV Sciences, Inc. Enters Into Definitive Agreement to Acquire Extract LabsNovember 21, 2024 | prnewswire.comCV Sciences Q3: Revenue Stable Amid New Launches, FinancingNovember 15, 2024 | benzinga.comCV Sciences Reports Q3 Revenue and Product LaunchNovember 15, 2024 | markets.businessinsider.comSee More Headlines CVSI Stock Analysis - Frequently Asked Questions How have CVSI shares performed this year? CV Sciences' stock was trading at $0.0338 at the start of the year. Since then, CVSI stock has decreased by 8.0% and is now trading at $0.0311. View the best growth stocks for 2025 here. How were CV Sciences' earnings last quarter? CV Sciences, Inc. (OTCMKTS:CVSI) released its quarterly earnings data on Thursday, August, 12th. The company reported ($0.03) earnings per share for the quarter, hitting the consensus estimate of ($0.03). The business earned $5.13 million during the quarter, compared to the consensus estimate of $5.12 million. CV Sciences had a negative trailing twelve-month return on equity of 101.85% and a negative net margin of 16.24%. How do I buy shares of CV Sciences? Shares of CVSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CV Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that CV Sciences investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Charlotte's Web (CWBHF), Cronos Group (CRON), KushCo (KSHB), NVIDIA (NVDA) and Organigram (OGI). Company Calendar Last Earnings8/12/2021Today2/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:CVSI Previous SymbolNASDAQ:CVSI CIK1510964 Webwww.cvsciences.com Phone(866) 290-2157Fax619-876-4321Employees70Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$3.10 million Net Margins-16.24% Pretax Margin-16.26% Return on Equity-101.85% Return on Assets-29.04% Debt Debt-to-Equity RatioN/A Current Ratio1.10 Quick Ratio0.28 Sales & Book Value Annual Sales$16 million Price / Sales0.36 Cash Flow$0.02 per share Price / Cash Flow1.75 Book Value$0.02 per share Price / Book1.56Miscellaneous Outstanding Shares184,794,000Free Float182,392,000Market Cap$5.75 million OptionableNot Optionable Beta0.69 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (OTCMKTS:CVSI) was last updated on 2/28/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBefore it hits CNBC: AI was just the warm-up act (see his next prediction)During a routine analysis of my proprietary data, something caught my eye. A small American tech company with ...InvestorPlace | SponsoredWhy 2026 will be a disaster for many AmericansWall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CV Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CV Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.